Introduction
Cellular programming and reprogramming technology (CPART) has provided a new way to investigate human development and disease. This technology is particularly useful for diseases in which the affected tissue is not available for cell purification and in which aspects of cell development are crucial for the pathology. The central nervous system (CNS) is a good example of tissue that falls into this category. Modeling human brain diseases using induced pluripotent stem cells (iPSC) or induced neural cells (iN) has remarkable potential to generate insights into understanding disease mechanisms and opening new avenues for clinical intervention. Researchers now have the opportunity to study human disease in living, developing neural cells that carry the disease-specific genetic variants that are present in the patient. In addition, CPART represents a fresh approach for developing original diagnostic tools and obtaining novel drug candidates for CNS therapy. Importantly, candidate compounds for treating CNS defects fail in clinical trials in over 90% of cases due to poor targeting, lack of efficacy, and unacceptable side effects (Kola and Landis, 2004) . We firmly believe that CPART can offer a valuable additional tool for screening and validating CNS compounds for pharmaceutical companies in the future.
In order for CPART to be successful and useful, our underlying and somewhat provocative assumption is that cellular deficiencies can be measured in vitro, recapitulating the phenotype that is relevant to human brain disease. These cellular deficiencies can be broken down into levels of relevance, ranging from highly relevant recapitulations of clinical observations to phenotypes not previously associated with the disease and to lack of in vitro phenotype all together. Ideally, the modeled in vitro phenotype is the same as the in vivo disease-causing phenotype that allows for the study of the mechanism and development of the disease. A less-pertinent model would result in an in vitro phenotype that is similar mechanistically but is clearly not the same as the in vivo phenotype and likely develops differently. This less-stringent level of relevance could still be used to screen compounds for reversal of phenotypes and could be used as a diagnostic tool. The least-stringent level of relevance would involve a phenotype that is unrelated in any known mechanistic way to the in vivo human disease but that could still potentially be used as a tool for the diagnosis of the disease. All these levels of relevance require the basic assumption that in vitro modeling is robust enough to detect a reliable and statistically meaningful difference between phenotypically normal and abnormal cells derived using CPART (Figure 1 ). This is particularly important in our view because there could be diseases in which the variability of phenotypes will be too big to achieve reliable statistical value. In these specific cases, more individuals could be included and/or more sensitive assays should be employed.
Nonetheless, as promising as this technology is, we are still in its early days. There are a number of roadblocks to be considered, and eventually overcome, before significant progress on disease mechanisms can be made and meaningful therapies can be proposed. In this Forum, we will discuss some of the current obstacles, beginning with reprogramming a patient biopsy and moving toward modeling disease-relevant phenotypes and proposing effective therapies (Figure 2 ).
Methods for Generating Reprogrammed Cells
Ever since the original procedure for producing iPSC was described by Takahashi and Yamanaka using four factors separately in retroviruses (Takahashi and Yamanaka, 2006) , the exact genes used and the delivery methods have been changing. While the mechanisms by which the reprogramming occurs remain incompletely understood, the robustness of the general approach is so clear that similar (though not exact) results can be achieved using a variety of methodologies. Interestingly, the vast majority of literature still employs viral integrating strategies. Random viral integration and incomplete silencing of reprogramming factors are likely among the major generators of variability between cell lines. We favor the idea that nonintegrative methods of reprogramming will be the best way to derive new cell lines in the future. The field will likely reach a consensus on some combination of soluble molecules and transient nonintegrating vectors that carry a small cluster of genes. The limitations on types of starting cells have also evolved from the original fibroblast to include many other somatic tissues of the body. One of the important developments has been direct programming of somatic biopsy cells (usually fibroblasts) to neural cells (reviewed in Zhou and Tripathi, 2012) . The initial reports of direct cellular programming revealed the disadvantage of not generating a renewable source of programmed cells, but recently several labs have shown that programming can be achieved to a proliferating population of neural precursor cells (iNPC) that can then be propagated and subsequently differentiated into mature neurons and glia (Zhou and Tripathi, 2012) . For the purpose of this review, we will use the term ''REPRO cells'' to represent both reprogrammed (iPSC) and programmed (directly differentiated) cells such as iNPC and iN.
Accessing the Fate of REPRO Cells
While the choice of donor cells and the method for generating the REPRO cells are critical considerations, another challenge is their differentiation into homogeneous populations of the cell type implicated in the disease phenotype. This is a rich field, and there is a steady flow of protocols for generating specific cell types, but much more work is required. Most strategies for cell fate specification are based on the achievements of in vivo developmental neurobiologists in the last 50 years. While the molecular pathways for generating specific cell types in the mouse do not always recapitulate a human in vitro setting, many of the pathways involved in cell fate decisions are conserved. Moreover, there is a surge in the drive to differentiate human REPRO cells to specific cell lineages, which will, in turn, provide the foundation for new knowledge about human neural development. An important cautionary note is that, with our existing technology, it is particularly challenging to generate mature human neurons in the dish. Most protocols currently available produce neurons that are comparable to cells at an immature fetal stage, although a lot of research is now dedicated to improving the neuronal outcome in terms of maturity and percentage of electrophysiologically active cells. Finally, much of the effort in vitro has been to establish protocols for differentiating cells into specific cell types through soluble molecules, including growth factors and activators or inhibitors of specific signaling pathways. For more complete fate determination, we will likely need to pay more attention to combinations of cell types and structures, including vasculature, which are critical in vivo for fate specification and maintenance.
Variability between Lines
As more iPSC lines are produced and shared, it has become increasingly clear to stem cell biologists that there is variability between cell lines that emerged after reprogramming. Differences between clonal lines have been detected at multiple levels, including variable expression profile levels, X-inactivation status on female lines, genetic instability, and differentiation potential (discussed in Hayden, 2011) . This observed variation could be attributed in part to the current protocols of reprogramming that include viral integration into the host DNA, as well as the intense cloning involving multiple passages of the cells that is required to apply CPART. It remains to be seen whether the widespread use of nonintegrating technology-which is readily available now-will reduce the variability of the cultures. Partial reprogramming and incomplete erasure of epigenetic marks has also been proposed as a source of variability (Hayden, 2011) , though some propose that this specific concern could be addressed by developing more stringent methodologies of selecting populations of REPRO cells that have undergone complete reprogramming. In the literature, few attempts have been made to implement general criteria for defining hallmarks for reprogramming and differentiation, but, given the fast pace of discovery in the field, more research is definitely needed to precisely dissect and deal with many sources of variability. An example of the dynamic nature of the iPSC characterization is the use of teratoma formation assays as the gold standard criterion for pluripotency validation. We support the view that teratoma generation is primarily qualitative, is difficult to standardize, and has questionable value for in vitro disease modeling (discussed in Mü ller et al., 2010). While broadly used as a reprogramming hallmark, many researchers are now questioning its value, particularly in light of reports showing that partially reprogrammed iPSC lines can also form teratomas (Chan et al., 2009) . Another important-and yet not fully understood-source of variability is the naturally occurring intrinsic variability between individuals. Specifically relevant to modeling mental illnesses will be the ability to dissect the phenotypic variability present in neuronal cells derived from nonaffected individuals from the clinically relevant differences present in neurons from affected patients.
One obvious way of addressing variability is to increase the number of controls and patients analyzed in combination with specific cohorts of patients who present common clinical histories and/or respond similarly to drugs. When possible, the use of genetically identical individuals (i.e., monogenetic twins) who are concordant or discordant for a mental disorder would also contribute to reducing variability and generating relevant disease hypotheses. In addition, generation of disease team consortiums would greatly facilitate CPART by enhancing the number of individuals analyzed (and new lines produced), promoting exchanges of cells and methodologies, and improving discussion. Different possible outcomes in disease modeling using cellular programming and reprogramming technology (CPART) and its relevance for effectively understanding disease mechanism, developing diagnostic tools, and finding novel therapies.
A very important methodology for this field is statistics. Given the aforementioned variability in the field, we support the use of multiple cell lines from each patient and ideally multiple patients with variable phenotypes. Careful analysis of the variance present in the data will indicate the minimal number of REPRO patient cell lines needed to obtain a statistically relevant measurement. It is likely that the number of cell lines needed will vary accordingly with the robustness of the assay performed. Sources of error with low numbers of subjects are plentiful in the field and increase the risk of both Type 1 and Type 2 errors. The success of this field depends on the ability to replicate findings from one laboratory to another. One of the great advantages of this field is that the principle reagent (the REPRO cell) can be banked and made available to other laboratories, meaning that we have an ever-expanding and -renewable source of research material that we can use to go back and compare, contrast, and add numbers to our analysis. Thus, while variability in methods of CPART and differentiation may mask or misrepresent some initial findings, the robust and meaningful phenotypes will emerge and persist, and the less-robust observations will not.
A further note of caution about variability relates to the variability that exists between individual cells from the same clone. This variability includes expression differences based on variable states of differentiation between, for example, two related neurons next to each other in the culture dish; other variance may be genomic and may result from intrinsic mechanisms of genomic mosaicism, attributed in part to mobile elements or driven by extrinsic factors such as the number of passages, which increases the risk of differential genome instability. It is likely that this is a source of variance that will not be resolved until more advanced methods of genomic analysis are available.
Modeling Brain Disease
Most successful reports involving disease modeling for neurological diseases to date utilize cells from patients with monogenetic disorders in which the gene mutation is characterized. Modeling monogenic brain disorders advanced the field, helped to establish the basic tools for culturing functional human neurons, and revealed meaningful neuronal phenotypes (Marchetto et al., 2010) . Importantly, monogenic disorder modeling presents the opportunity to perform gain-and loss-offunction studies to confirm that the neuronal phenotypes observed are disease specific, as opposed to a general, nonspecific effect.
The advantages of studying monogenic diseases are many; not the least important is proving, in an isogenic nondiseased cell, that the homologous recombination of the diseased gene is necessary and sufficient for recapitulating the in vitro disease phenotype. Nonetheless, a large percentage of brain disorders (i.e., autism and schizophrenia) have a complex nature and are likely multifactorial: a combination of mutations in several genes (as opposed to mutations in only one gene) and extrinsic factors (influence of neighbor cells and environment) are involved in the disease pathology.
Crucial for the future of modeling complex CNS diseases will be developing novel, more-sensitive tools and improving methodology and analysis such that they will consistently pick up subtle but important differences between controls and affected cell lines (reviewed in Marchetto et al., 2011) .
New neuronal differentiation protocols can obtain particular subtypes of neurons that are relevant to particular diseases (e.g., dopaminergic neurons for Parkinson's disease, hippocampal and cholinergic neurons for Alzheimer's disease, motor neurons for amyotrophic lateral sclerosis). In addition, improving the protocols for evaluating neuronal connectivity properties, synaptic plasticity, and electrophysiological functional outcomes will definitely be of great value in detecting disease-related phenotypes. Examples of techniques that are already available but not yet widely employed in the field are calcium imaging, light-activated channelrhodopsins, uncaged glutamate, transynaptic labeling using virus, multielectrode arrays, single-cell expression analysis, high-resolution live imaging for spine motility and maturation, synaptic protein recruitment, and axonal transporting dynamic visualization.
Combining ideas and technologies from established fields will be highly beneficial to this nascent field. A practical example is the recent incorporation of biomaterials and bioengineering techniques for improved differentiation of iPSC cultures. New alternative methods for better compartmentalization and isolation of neuronal processes using microfluidic chambers have been explored and implemented in primary neural cultures. Compartmentalization of neurons using engineered devices would allow comparisons of the dynamic behavior and molecular anatomy of control versus diseased neurons in culture. Additionally, using engineered tridimensional biomatrices to simulate tissue structures may more authentically recapitulate in vivo neuronal branching and connectivity and potentiate a more complete in vitro maturation.
For many complex CNS diseases, extrinsic factors play a crucial role in the neuronal pathology. Injury to neurons can be conferred by immunological response from neighbor cells (microglia) and/or from a decline in the health of supporting glial cells (astrocytes and oligodendrocytes). The incorporation of niche cells into in vitro models could improve our understanding of the non-cell-autonomous effects on diseased neurons. New technology for the generation of homogeneous populations of glial cells from iPSCs is now available (Krencik and Zhang, 2011; Yuan et al., 2011) . Another alternative for teasing out non-cell-autonomous effects on more mature and integrated neurons is in vivo grafting of REPRO cells in rodent brains. Studying the anatomy and function of transplanted neurons over time informs studies of neurodevelopmental aspects of the disease and of cell-autonomous versus nonautonomous elements. Developmental hallmarks such as neuronal pruning, dendritic branching, spine formation, and maturation could be dynamically observed as transplanted neural progenitors differentiate into neurons over time. State-ofthe-art intracranial live-imaging techniques coupled with electrophysiological studies could facilitate studies of functional integration properties from neurons in real time. Transplantation may also lead to the generation of specific subtypes of neurons that are difficult to produce through in vitro differentiation protocols. These transplantation studies ideally recapitulate the in vivo characteristics of human cells more authentically. Because cells need to be implanted at an early enough time to allow host factors to more accurately act on the REPRO cells, this process may lead to chimerism, so both technical and ethical challenges remain.
Advanced whole-genome sequencing technology facilitates detection of new mutations and relevant variations in complex genetic diseases leading to common clinical outcomes. Combining in-depth DNA sequencing analysis with in vitro disease-relevant neuronal phenotypes, high-throughput proteomics/ metabolomics data, and longitudinal clinical studies of predefined cohorts of patients will certainly provide a very comprehensive volume of information about disease features. What is clear is that while CPART is evolving, so is whole-genome technology; its depth and accuracy are changing and improving so rapidly that each new analysis is almost outdated by the time it is published.
There are certainly opportunities available for CPART-based preclinical studies at all stages of drug development. Drug screening success for brain diseases would depend on the relevance, robustness, and scalability of the detected in vitro phenotype. New initiatives for drug screening using patient-reprogrammed cells are already in place, with the idea of taking advantage of assays developed in academia combined with Food and Drug Administration-approved drugs that have been repurposed.
Conclusion
As with many new marriages that bring together leading-edge technology with potential clinical applications, we are in the honeymoon stage. Evidence is pouring in every day through publications and opinion pieces that reveal new models, extraordinary results, and promising new applications. But of course every honeymoon comes to an end, and the staying power of this marriage will depend on its ability to stand the test of time and scrutiny. Many of the basic assumptions will be challenged, and many more technical hurdles will need to be overcome, especially the convergence on the best and most-reliable methods for programming and reprogramming cells. In addition, optimal ways to selectively specify cell fates that accurately reflect the in vivo behavior of cells will need to be developed. Also challenging will be the development of a variety of tools that most sensitively and reliably measure functional phenotypes that are relevant to disease. While many aspects of this marriage between basic and clinical research will change and likely improve, we predict that this hybrid research approach will not go away but rather will become an essential tool for basic biology and translational medicine.
